1. Table S1: Antibodies Used for Flow Cytometric Analysis

2. Table S2: Contemporaneous Control Cohort/Std Rx Cohort Characteristics
Age
Average Age
48 Years
Sex
% Male
41%
Primary Disease
% AML
50%
% ALL
14%
% Other Primary Disease
36%
HLA
% HLA matched
77%
Conditioning Regimen
% Bu/Cy
% TBI/Cy
18%
% Flu/Mel
46%
Graft Type
% PBMC Grafts
91%
Neutrophil Engraftment
Mean Day of Neutrophil Engraftment
16 days
CD4 Reconstitution
Day 100 CD T cell Count
282 +/- 44 cells/ml
GVHD
% Grade II-IV AGVHD Prior to Day 100
% III-IV AGVHD Prior to Day 100
17%
% Receiving GVHD Salvage Therapy
Relapse
% Relapse
Survival
% Surviving at 18 months post-transplant
72%
Table S2 Need % males and Day 100 CD4+ T cell count

3. Table S3: StdRx Patient and Transplant Characteristics
UPN
Age/Sex
Disease and Status
HLA matching
(mismatch)
CMV Status (R/D)
Preparative Regimen
Graft Source 30
ALL, primary induction failure
8/8
+/-
Bu/Cy
PBSC 35
Myelofibrosis
7/8 (A antigen)
-/+ 66
MDS
+/+
Flu/Mel 48
Chronic phase CML, TKI resistant/intolerant
7/8 (C antigen) 64
ALL, CR2
TBI/Cy 41
7/8 (B antigen)
Bu/Cy/ATG 12
ALL, CR1
TBI/Cy/VP16 BM
Table S3

4. Table S4 StdRx Clinical Outcomes

5. 100% XY.
97.5% XX.
Grade II AGvHD involving the skin on d+48.
Grade III AGvHD involving the gut d+35, steroid refractory, treated with infliximab.
Grade IV AGvHD involving the skin, liver, and gut, steroid refractory, treated with infliximab.
Grade III AGvHD involving the gut on d+44, steroid refractory, treated with infliximab.
Atypical pneumonia d+12.
Parainfluenza – not intubated, not requiring ICU stay on d+10; enterobacter bacteremia – requiring hospitalization and IV abx on d+117.